Bogart Jeffrey A, Seagren Stephen L, Glicksman Arvin
Upstate Medical University, Syracuse, New York, USA.
Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3628s-34s. doi: 10.1158/1078-0432.CCR-06-9011.
Radiation oncology initiatives have been an integral component in the evolution of multidisciplinary research in the Cancer and Leukemia Group B. Although early studies in the Group primarily focused on chemotherapy for hematologic and pediatric malignancies, the Radiation Oncology Committee was established in 1972, reflecting the broadening scope of clinical investigation with an increased emphasis on solid tumor research. A major early contribution of the Radiation Oncology Committee was the recognition of the importance of formalized radiation quality review, which led to the development of the Quality Assurance Review Center. The committee has been instrumental in designing trials, in conjunction with our medical oncology and surgical oncology colleagues, to assess multimodality therapy. The results of many of these studies have had important implications for clinical practice. Recent efforts have explored our major research theme of treatment intensification via radiotherapy dose modulation and novel combinations of radiotherapy with sensitizing agents, with an emphasis on safely implementing advanced technologies in the cooperative group setting.
放射肿瘤学项目一直是癌症与白血病B组多学科研究发展中不可或缺的组成部分。尽管该组早期的研究主要集中于血液学和儿科恶性肿瘤的化疗，但放射肿瘤学委员会于1972年成立，这反映出临床研究范围的扩大，且日益重视实体瘤研究。放射肿瘤学委员会早期的一项主要贡献是认识到正式的放射质量审查的重要性，这促成了质量保证审查中心的建立。该委员会与我们的医学肿瘤学和外科肿瘤学同事合作，在设计评估多模式治疗的试验中发挥了重要作用。其中许多研究结果对临床实践具有重要意义。最近的努力探索了我们通过放疗剂量调制以及放疗与增敏剂的新型联合来强化治疗的主要研究主题，重点是在协作组环境中安全地应用先进技术。
